Amersham, UK / Malvern, PA – December 13, 2016 – Phlexglobal, the world-renowned thought leaders and specialists in the provision of electronic Trial Master File (eTMF) systems and services to the life sciences industry, today announced a significant investment by funds managed by Vitruvian Partners (“Vitruvian”). The transaction establishes Vitruvian as majority shareholder of Phlexglobal, while previous majority investor Bridgepoint Development Capital (“BDC”) will exit the company.
Bridgepoint Development Capital ('BDC') is to acquire a majority shareholding in Vitamin Well AB, a high growth, market-leading business in the functional drinks sector, for an undisclosed sum.
Bridgepoint, the European private equity group, is to sell Oasis Dental Care, the UK’s leading private dental services provider, to Bupa in a transaction valuing the business at £835million.
European credit management services group Intrum Justitia is to acquire UK debt purchaser 1st Credit from private equity firm Bridgepoint for an enterprise value of £130m, subject only to regulatory consent.
Bridgepoint, the international private equity investor, is to acquire the Agro Business interests of the listed conglomerate Sapec Group (Sapec S. A. BE), in a transaction valuing the business at €456 million. The acquired entity, Sapec Agro Business is the Iberian market leader in off-patent crop protection products and also speciality crop nutrition.